Compare Novo Nordisk A/S (NVO) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs IAC/Interactivecorp — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while IAC/Interactivecorp trades at $40.89 (market cap $3.05B). The key difference: Novo Nordisk A/S is far larger — about 54.2× IAC/Interactivecorp's market cap, and Novo Nordisk A/S pays a 4.71% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and IAC/Interactivecorp for 79 Days on average.
| NVO | PPLI | |
|---|---|---|
Market Cap | $165.31B | $3.05B |
Volume | 11,432,838 | 931,019 |
Sector | Health | Media |
52-Week High | $63.98 | $47.62 |
52-Week Low | $35.29 | $31.52 |
Typical Hold Time | 116 Days | 79 Days |
Enterprise Value | $179.56B | $3.53B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
PPLI trades at $40.93, up 0.84% today, with a bullish technical signal from moving averages and strong analyst support (71% buy ratings). Recent news highlights potential M&A interest from MGM Resorts, driving volatility. Financially, the company shows mixed results with a negative net income in 2025 but improved revenue stability and attractive valuation ratios like a P/E of 6.92 and P/B of 0.6.
The outlook is cautiously optimistic due to takeover speculation and low valuation, but risks include inconsistent earnings, high debt, and industry challenges. Further upside depends on successful strategic moves or M&A realization, while failure to improve profitability could pressure the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
